Tidsperiod: 2012-01-01 till 2014-12-31
Projektledare: Britt Skogseid
Medarbetare: Peter Stålberg, Andreea Barbu
Budget: 1 500 000 SEK
This project is a translational project with a twin focus: A/ adrenocortical carcinoma (ACC) and B/ pancreatic endocrine tumors. A/ We have run a phase III randomized, prospective, controlled, open -label, parallel group study of treatment of metastatic ACC since 2004. The clinical part is now over (recruitment has followed the timeplan and events, deaths, have occurred as anticipated). Statistical analysis is ongoing. The study will impact treatment of this rare and aggressive disease. Our network is now organized, and several new studies are being launched, i.e. adjuvant treatment, PET studies, tumor bank for whole-genome seqencing, tissue-array. In my group also perform in vitro (cell culture) and in vivo (xenograft) studies of a Hedgehog inhibitor (itraconazole) for ACC. B/ We have a comprehensive collection patient data and pancreatic endocrine tumors (sporadic as well as hereditary, MEN1), We will continue to evaluate our management strategies for MEN1patients as well as applied treatment protocols for patients with malignant tumors. We study the physiological role of the MEN1 suppressor gene by analyzing the molecular effects of inactivation in endocrine cells; siRNA, expression array and proteomics. We hypothesize that MEN1 is a haploinsufficient suppressor and use a knock-out mouse model for harvesting of islets and microadenomas (collagenase treated pancreas). We also study Pancreatic Stellate cells in MEN1 to establish their potential role in tumorigenesis.